<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418610</url>
  </required_header>
  <id_info>
    <org_study_id>Bayer Rosacea</org_study_id>
    <nct_id>NCT03418610</nct_id>
  </id_info>
  <brief_title>Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea</brief_title>
  <official_title>Azelaic Acid Foam 15% in the Treatment of Papulopustula Rosacea: An Evaluation of Photographic Evidence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Center of the Carolinas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Center of the Carolinas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being performed to evaluate the photographic evidence of the efficacy&#xD;
      and tolerability of Azelaic Acid Foam 15% in the treatment of papulopustular rosacea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single site, single arm open label study of Azelaic Acid foam 15% for the treatment&#xD;
      of moderate to severe papulopustular rosacea. All patients will apply Azelaic Acid foam twice&#xD;
      daily. At scheduled visits, high resolution equipment will be used to measure 3D&#xD;
      topographical values for elevation of papules and pustules to objectively evaluate reduction&#xD;
      of papulopustular lesions. Investigator and subject assessments will also be completed to&#xD;
      assess the level of rosacea at weeks 4,8 and 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Actual">January 9, 2019</completion_date>
  <primary_completion_date type="Actual">January 9, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Site, Single Arm Open Label Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory Lesion Count</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change in inflammatory lesion counts at week 12 compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Severity of Disease by Investigator Global Assessment, Score of 0 (Clear) - 4(Severe)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Rosacea, Papulopustular</condition>
  <arm_group>
    <arm_group_label>Open Label Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Azelaic Acid Foam 15% applied twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic Acid foam 15%</intervention_name>
    <description>mild to moderate rosacea</description>
    <arm_group_label>Open Label Single Arm</arm_group_label>
    <other_name>Finacea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects age 18 or older.&#xD;
&#xD;
          2. Diagnosis of moderate to severe papulopustular rosacea with IGA of 3- moderate or&#xD;
             4-severe.&#xD;
&#xD;
          3. Presence of 12 - 50 inflammatory lesions and persistent erythema with or without&#xD;
             telangiectasia.&#xD;
&#xD;
          4. Subjects must read, understand, and sign the Informed Consent.&#xD;
&#xD;
          5. Subjects must be willing and able to comply with study procedures and visit schedule&#xD;
             requirements.&#xD;
&#xD;
          6. Women of childbearing potential that are willing to use an acceptable method of&#xD;
             contraception during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active or localized or systemic infections.&#xD;
&#xD;
          2. Subjects must not be immunocompromised.&#xD;
&#xD;
          3. Known unresponsiveness or allergy to azelaic acid.&#xD;
&#xD;
          4. Subjects unlikely to comply with the protocol, e.g. mental condition rendering the&#xD;
             patient unable to understand the nature, scope, and possible consequences of the&#xD;
             clinical study, uncooperative attitude or unlikelihood of completing the study (e.g.&#xD;
             drug or alcohol abuse).&#xD;
&#xD;
          5. Subjects must not be pregnant or breastfeeding.&#xD;
&#xD;
          6. Presence of dermatoses that might interfere with the ability to diagnose and/or&#xD;
             evaluate rosacea.&#xD;
&#xD;
          7. Presence of other types of rosacea.&#xD;
&#xD;
          8. Laser surgery on the face for the treatment of telangiectasia or other conditions&#xD;
             within 6 weeks of study enrollment.&#xD;
&#xD;
          9. Use of medications or products for the treatment of rosacea or other medical&#xD;
             conditions within the following time periods prior to study enrollment. Use of these&#xD;
             medications will be prohibited during the trial.&#xD;
&#xD;
             Topical Prescription or Nonprescription medications 6 weeks Oral retinoids 6 months&#xD;
             Tetracycline (ex. doxycycline, minocycline 2 months Corticosteroids 4 weeks&#xD;
             Erythromycin or azithromycin 4 weeks Other systemic medications to treat rosacea 6&#xD;
             weeks&#xD;
&#xD;
         10. Refusal to sign the Informed Consent document or Photo Release document and/or refusal&#xD;
             to comply with all follow-up requirements.&#xD;
&#xD;
         11. Use of medications that are known to cause flushing.&#xD;
&#xD;
         12. Dose changes in the last 90 days or initiation of beta-blockers, vasodilators,&#xD;
             vasoconstrictors, nonsteroidal anti-inflammatory drugs, hormone therapy, and/or other&#xD;
             drugs known to cause acneform eruptions.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Schlesinger, MD, FAAD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center of the Carolinas</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rosacea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

